Latest Breaking News On - Marc engelhardt - Page 7 : comparemela.com

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Basel stadtUnited statesNils schrBasel allschwilAllschwil hegenheimermattwegMarc engelhardtAsahi kasei pharmaLaurenz kellenbergerDavid veitchUs department of healthHuman servicesBiomedical advanced researchDrug administrationMerck coAdministration for strategic preparednessDevelopment authority

Basilea Pharmaceutica AG: Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing

Basel stadtUnited statesNils schrBasel allschwilMarc engelhardtAsahi kasei pharmaLaurenz kellenbergerDavid veitchUs department of healthHuman servicesHead of corporate communications investor relationsBiomedical advanced researchDrug administrationMerck coAdministration for strategic preparednessDevelopment authority

Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

Basel/Allschwil, Switzerland, December 19, 2022 Basilea Pharmaceutica Ltd. , a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial. | December 19, 2022

Basel stadtBasel allschwilNils schrMarc engelhardtBasilea pharmaceutica international ltdHead of corporate communications investor relationsSillajen incSwiss exchangeBasilea pharmaceutica ltdChief medical officerPharmaceutica ltdCorporate communicationsPharmaceutica international ltdBasilea pharmaceutica ag stock exchangePress releaseEvere bsln ch0011432447

ERADICATE phase 3 study results highlight the potential

Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to.

Basel stadtUnited statesMikael saulayMarc engelhardtSarahb doernbergSarae cosgroveTimothyc jenkinsDaniel ionescuIvan titovNicholasa turnerHarald seifertVanceg fowler jrBoiko atanasovOleksandr pavlovMaziar assadi gehrThomasl holland

Basilea Pharmaceutica AG: Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022

First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or without aztreonam Basel/Allschwil, Switzerland, October

United statesSouth africaBasel stadtRepublic of south africaNils schrMikael saulayMarc engelhardtSarahb doernbergSarae cosgroveDaniel ionescuTimothyc jenkinsIvan titovNicholasa turnerHarald seifertVanceg fowler jrBoiko atanasov